XML 52 R39.htm IDEA: XBRL DOCUMENT
v3.8.0.1

COLLABORATIVE ARRANGEMENTS (Details) - USD ($) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Less: amortization of capitalized fees paid to a related party |  |  |  |  |  |  |  |  | $ (13,823,000) | $ (13,823,000) | $ (13,823,000) |
Royalty revenue |  |  |  |  |  |  |  |  | 214,118,000 | 132,684,000 | 53,064,000 |
Strategic alliance - MABA program license |  |  |  |  |  |  |  |  | 3,099,000 | 885,000 | 885,000 |
Total net revenue | $ 69,520,000 | $ 48,643,000 | $ 58,562,000 | $ 40,492,000 | $ 43,612,000 | $ 33,309,000 | $ 32,472,000 | $ 24,176,000 | 217,217,000 | 133,569,000 | 53,949,000 |
GSK |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Total net revenue |  |  |  |  |  |  |  |  | $ 217,217,000 | 133,569,000 | 53,949,000 |
LABA collaboration and Strategic Alliance agreements | GSK |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Percentage of economic interest in any future payments made under the agreements |  |  |  |  |  |  |  |  | 15.00% |  |  |
Long-acting beta agonist (LABA) collaboration | GSK |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalties from a related party |  |  |  |  |  |  |  |  | $ 227,941,000 | 146,507,000 | 66,887,000 |
Less: amortization of capitalized fees paid to a related party |  |  |  |  |  |  |  |  | (13,823,000) | (13,823,000) | (13,823,000) |
Royalty revenue |  |  |  |  |  |  |  |  | 214,118,000 | 132,684,000 | 53,064,000 |
Milestone fees paid |  |  |  |  |  |  |  |  |  |  |  | $ 220,000,000
Obligation for milestone payments | $ 0 |  |  |  |  |  |  |  | $ 0 |  |  |
Percentage of economic interest in any future payments made under the agreements |  |  |  |  |  |  |  |  | 15.00% |  |  |
Long-acting beta agonist (LABA) collaboration | GSK | RELVAR/BREO |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalties from a related party |  |  |  |  |  |  |  |  | $ 198,726,000 | 128,638,000 | 59,188,000 |
Royalty rate for first level of annual global net sales (as a percent) |  |  |  |  |  |  |  |  | 15.00% |  |  |
Annual global sales level used to determine royalty rate |  |  |  |  |  |  |  |  | $ 3,000,000,000 |  |  |
Royalty rate for sales above first level of annual global net sales (as a percent) |  |  |  |  |  |  |  |  | 5.00% |  |  |
Long-acting beta agonist (LABA) collaboration | GSK | ANORO |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalties from a related party |  |  |  |  |  |  |  |  | $ 29,036,000 | 17,869,000 | 7,699,000 |
Long-acting beta agonist (LABA) collaboration | GSK | ANORO | Minimum |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  |  |  |  |  |  |  | 6.50% |  |  |
Long-acting beta agonist (LABA) collaboration | GSK | ANORO | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  |  |  |  |  |  |  | 10.00% |  |  |
Long-acting beta agonist (LABA) collaboration | GSK | TRELEGY |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalties from a related party |  |  |  |  |  |  |  |  | $ 179,000 | 0 | 0 |
Long-acting beta agonist (LABA) collaboration | GSK | TRELEGY | Minimum |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  |  |  |  |  |  |  | 6.50% |  |  |
Long-acting beta agonist (LABA) collaboration | GSK | TRELEGY | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  |  |  |  |  |  |  | 10.00% |  |  |
Strategic alliance - MABA program license | GSK |  |  |  |  |  |  |  |  |  |  |  |
Information related to collaborative arrangements |  |  |  |  |  |  |  |  |  |  |  |
Strategic alliance - MABA program license |  |  |  |  |  |  |  |  | $ 3,099,000 | $ 885,000 | $ 885,000 |

X
- Definition Represents the amortization of capitalized fees paid to a related party. + References No definition available. + Details
Name: | inva_AmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the royalty rate for combination products. + References No definition available. + Details
Name: | inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum amount of potential milestone payments that could be payable. + References No definition available. + Details
Name: | inva_CollaborativeArrangementObligationForMilestonePayments
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of registrational and launch-related milestone fee paid under the collaborative arrangement. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRegistrationalAndLaunchRelatedMilestoneFeesPaid
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. + References No definition available. + Details
Name: | inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of economic interest in any future payments made under the agreements. + References No definition available. + Details
Name: | inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property, excluding revenue from collaborative arrangements. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents. + References No definition available. + Details
Name: | inva_RoyaltyRevenueFromRelatedPartyNet
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.1(c)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999 + Details
Name: | us-gaap_RevenueFromRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_LABACollaborationAndStrategicAllianceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_LABACollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=inva_TrelegyElliptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |